VERICEL CORPORATION Lessee, Operating Lease, Liability, to be Paid
VERICEL CORPORATION (VCEL) had Lessee, Operating Lease, Liability, to be Paid of $131.55 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue · last filed 2026-02-26
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid $131.55M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid $145.22M.
- 2023-09-30: Lessee, Operating Lease, Liability, to be Paid $157.76M.
- 2023-06-30: Lessee, Operating Lease, Liability, to be Paid $159.54M.
| Period end | Lessee, Operating Lease, Liability, to be Paid |
|---|---|
| 2025-12-31 | $131.55M 10-K · filed 2026-02-26 |
| 2024-12-31 | $145.22M 10-K · filed 2025-02-27 |
| 2023-09-30 | $157.76M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $159.54M 10-Q · filed 2023-08-02 |
| 2022-12-31 | $61.10M 10-K · filed 2023-02-23 |
| 2021-12-31 | $66.39M 10-K · filed 2022-02-24 |
| 2021-09-30 | $4.93M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $4.95M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $4.30M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $72.33M 10-K · filed 2021-02-24 |
| 2019-12-31 | $38.00M 10-K · filed 2020-02-25 |
| 2019-09-30 | $39.09M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $38.38M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $39.33M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |